ArticleDrug design, development and therapy2025
Mucoadhesive Mini-Containers with Unidirectional Drug Release Capacity for Macromolecular Therapeutics.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Peptide-based therapeutics have gained widespread attention for their high specificity and efficacy. However, their oral delivery remains challenging owing to their poor stability and bioavailability in the gastrointestinal environment and limited membrane permeability. To address these barriers, we have designed a novel mini-container system with unidirectional drug release and enhanced mucoadhesion capacities. Methods: Mini-containers composed of ethyl cellulose shells of varying degrees of viscosity were fabricated using a simple molding process and integrated with catechol-conjugated chitosan (CC) to improve their mucosal adhesion capacity and structural stability. Results: The catechol substitution levels were optimized (CC-A, CC-B, and CC-C), with the CC-C formulation exhibiting the highest degree of substitution (20.93%) and superior adhesion capacity, maintaining 80% attachment on porcine small intestinal mucosa after 72 h. Insulin, a model peptide drug, was successfully loaded into the CC-C mini-containers, and circular dichroism spectroscopy analysis confirmed that its secondary structure remained intact. The insulin content in the mini-containers, as determined by HPLC-UV analysis, demonstrated consistency across formulations: 101.1 ± 2.4% for 1% CC-C, 95.4 ± 3.8% for 2% CC-C, and 100.0 ± 1.8% for 3% CC-C, while in-vitro dissolution and Franz diffusion cell studies demonstrated its sustained and unidirectional release. After 12 hours of dissolution, the 3% CC-C formulation showed a release rate of 26.22 ± 2.23%, while the 1% CC-C formulation exhibited a release rate of 53.11 ± 0.25%. Catechol-mediated crosslinking significantly slowed the release rate relative to that of controls. The robust structure of the mini-containers fabricated with high-viscosity ethyl cellulose exhibited a mechanical strength of 13.21 ± 0.50 N, comparable to that of commercial enteric capsules (10 N), ensuring durability under gastrointestinal conditions. Conclusion: This study shows the potential of mini-container technology for the stable and prolonged oral delivery of macromolecular therapeutics. However, further investigation is required to confirm its effectiveness in-vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.